RecruitingPhase 4

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

United States75 participantsStarted 2023-08-25

Plain-language summary

The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. History of hypertension
✓. Seated systolic BP \< 180 mmHg and diastolic \< 110 mmHg if on antihypertensives
✓. Seated systolic BP 141-200 mmHg and/or diastolic BP 90-114 mmHg if not on antihypertensives
✓. LVH by echocardiogram
✓. For men: interventricular septum thickness ≥ 12mm
✓. For women: interventricular septum thickness ≥ 11mm
✓. We will also allow inclusion of people with treated hypothyroidism, pre-diabetes and diabetes controlled by diet, exercise, and/or metformin.

What they're measuring

Change in myocardial flow reserve

Timeframe: 9 months

Trial details

NCT IDNCT05593055

SponsorBrigham and Women's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-04-01

Contact for this trial

Gail K Adler, MD, PhD

781-223-2686 gadler@bwh.harvard.edu

View on ClinicalTrials.gov More Hypertension trials